Janus Henderson Group PLC Caribou Biosciences, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.3 - $7.78 $50,116 - $90,675	11,655 Added 85.21%	25,333 $134,000
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $5 - $11	1 Added 0.01%	13,678 $85,000
Q3 2022 Nov 14, 2022	SELL	$5.34 - $12.79 $331 - $792	-62 Reduced 0.45%	13,677 $144,000
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $627,621 - $1.2 Million	-123,063 Reduced 89.96%	13,739 $75,000
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $8.72 Million - $15.9 Million	-1,035,923 Reduced 88.33%	136,802 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$14.59 - $23.26 $976,464 - $1.56 Million	-66,927 Reduced 5.4%	1,172,725 $16.7 Million
Q3 2021 Nov 16, 2021	BUY	$15.75 - $30.29 $19.5 Million - $37.5 Million	1,239,652 New	1,239,652 $28.5 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $119M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.